BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 12393440)

  • 1. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
    Davies SM; Ruggieri L; DeFor T; Wagner JE; Weisdorf DJ; Miller JS; Velardi A; Blazar BR
    Blood; 2002 Nov; 100(10):3825-7. PubMed ID: 12393440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
    Giebel S; Locatelli F; Lamparelli T; Velardi A; Davies S; Frumento G; Maccario R; Bonetti F; Wojnar J; Martinetti M; Frassoni F; Giorgiani G; Bacigalupo A; Holowiecki J
    Blood; 2003 Aug; 102(3):814-9. PubMed ID: 12689936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation.
    Sivula J; Volin L; Porkka K; Vettenranta K; Itälä M; Partanen J; Turpeinen H
    Transpl Immunol; 2007 Jul; 18(1):62-6. PubMed ID: 17584604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
    Verheyden S; Schots R; Duquet W; Demanet C
    Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
    Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
    Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
    Beelen DW; Ottinger HD; Ferencik S; Elmaagacli AH; Peceny R; Trenschel R; Grosse-Wilde H
    Blood; 2005 Mar; 105(6):2594-600. PubMed ID: 15536148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
    Ruggeri L; Capanni M; Casucci M; Volpi I; Tosti A; Perruccio K; Urbani E; Negrin RS; Martelli MF; Velardi A
    Blood; 1999 Jul; 94(1):333-9. PubMed ID: 10381530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
    Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
    Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
    Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
    Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
    Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
    Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of KIRs and KIR ligands in hematopoietic transplantation.
    Velardi A
    Curr Opin Immunol; 2008 Oct; 20(5):581-7. PubMed ID: 18675345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [KIRs on human NK cells and in relation with HLA class I antigen--review].
    Dou LP; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):627-30. PubMed ID: 16800958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component.
    Hsu KC; Pinto-Agnello C; Gooley T; Malkki M; Dupont B; Petersdorf EW
    Tissue Antigens; 2007 Apr; 69 Suppl 1():42-5. PubMed ID: 17445161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.